Lupichromone

Eriosemation demonstrates significant androgen receptor (AR) antagonistic activity, indicating its potential for prostate cancer research. This small molecule is suitable for both in vitro binding assays and in vivo model studies to evaluate therapeutic strategies targeting androgen signaling pathways.